亿帆医药戒毒胶囊审批结果未出

Group 1 - The clinical trial results for the detoxification capsule developed by Yifan Pharmaceutical (002019.SZ) have met the expected goals as of August 20 [1] - Following the announcement, the company's stock price fell by over 1% during trading on August 21, attributed to industry-wide adjustments after previous significant gains [1] - The product has applied for breakthrough therapy designation, with an expected approval result around September 20, based on a 45-working-day review period [1] Group 2 - The company acknowledges uncertainties regarding the approval for market launch by the National Medical Products Administration [1] - Yifan Pharmaceutical is committed to actively advancing the research project in accordance with national regulations and will fulfill information disclosure obligations regarding project progress [1]